Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002963392 | SCV003288761 | uncertain significance | not provided | 2022-07-13 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). This variant has not been reported in the literature in individuals affected with PMPCB-related conditions. This variant is present in population databases (rs202239518, gnomAD 0.02%). This sequence change replaces leucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 119 of the PMPCB protein (p.Leu119Met). |
Laboratory of Inherited Metabolic Diseases, |
RCV003108139 | SCV003762163 | uncertain significance | Multiple mitochondrial dysfunctions syndrome 6 | 2023-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004065079 | SCV005009732 | uncertain significance | Inborn genetic diseases | 2022-07-19 | criteria provided, single submitter | clinical testing | The c.355C>A (p.L119M) alteration is located in exon 4 (coding exon 4) of the PMPCB gene. This alteration results from a C to A substitution at nucleotide position 355, causing the leucine (L) at amino acid position 119 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |